Phenom Named Strategic Leader in 2024 Fosway 9-Grid™ for Talent & People Success
10.10.2024 11:30:00 CEST | Business Wire | Press release
Positioning Recognises Phenom’s Impact on Helping Europe’s Largest Companies Solve HR’s Biggest Talent Management Challenges
Phenom has been named a Strategic Leader in the 2024 Fosway 9-Grid™ for Talent and People Success, a testament to the value delivered by the AI-powered Phenom Intelligent Talent Experience platform, which makes new employees productive faster, enhances development and increases retention.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241010930504/en/

Phenom has been named a Strategic Leader in the 2024 Fosway 9-Grid™ for Talent and People Success, a testament to the value delivered by the AI-powered Phenom Intelligent Talent Experience platform, which makes new employees productive faster, enhances development and increases retention. (Graphic: Business Wire)
Fosway Group identifies Strategic Leaders as companies that provide a rich suite of capability across a broad scope of features and have the sophistication to consistently meet the needs of complex enterprise-scale customers. Strategic Leaders are also recognised by Fosway Group for having strong market performance and customer advocacy; as a result, they are frequently selected by such organisations and consistently meet their needs.
From labour shortages to changing skills and emerging technologies, the European job market continues to transform. To navigate this, talent management professionals, HR leaders and HRIT teams must collaborate to make new employees productive from day one, provide continued development opportunities, identify and fill skills gaps and encourage long-term retention.
“As European organisations wrestle with how they become more skills-based, they have been looking at how their tech stack solves that problem,” said David Wilson, CEO and founder of Fosway Group. “With their roots in skill-based hiring and their growing specialist capability around internal mobility and skills intelligence, Phenom has been well placed to provide a springboard to those answers for enterprise buyers. And their growing service and platform maturity has been pivotal in making them a Strategic Leader for talent experience on the Fosway 9-Grid™ this year.”
Phenom’s solution for talent and people success centers around delivering hyper-personalised experiences for employees, their managers and talent management. These experiences are enhanced with X+, Phenom’s Generative AI that is purpose-built for HR, to support key areas including:
- Pre-boarding: Provides a streamlined, transparent and easy experience that makes a lasting positive impact for new employees.
- Onboarding: Shortens time to productivity for new employees and automates tedious, manual tasks for HR teams.
- Talent Marketplace: Gives employees visibility to internal job and growth opportunities, as well as refers quality talent for critical roles.
- Career Pathing: Helps employees discover their next internal career move and the skills needed to get there. X+ provides an always on career coach that responds to their questions with personalised development plans.
- Cross-boarding: Supports employee transitions to new positions and teams.
- Workforce Intelligence: Identifies skill and competency gaps and insights within each department and at the enterprise level.
- Learning and Development: Educates internal talent with personalised courses to support upskilling and reskilling based on their projected career paths.
- Mentoring: Empowers and supports employees throughout their career journey by connecting them with best-fit mentors.
- Gigs: Provides real-world experience through short-term work and project-based tasks allowing employees to develop their skills.
- Employee Resource Groups: Fosters engagement, community and a sense of belonging.
- Offboarding: Streamlines experiences for employees leaving the organisation.
“Phenom’s positioning is a testament to our ongoing innovation and helping European organisations embrace a skills-based approach to talent management, growth and retention,” said John Deal, Sr. Director, Product Marketing at Phenom. “As Europe contends with an evolving workforce landscape, it has never been more critical to leverage intelligence to enable smarter and more impactful career development, upskilling and workforce planning decisions.”
Phenom’s placement also complements the company’s four-year positioning as a Strategic Leader in the Fosway 9-Grid™ for Talent Acquisition, showcasing the end-to-end benefits of using its full Intelligent Talent Experience platform. Over 700 global and diverse companies are using the Phenom platform to help:
- Candidates find and choose the right job faster.
- Employees develop their skills and evolve.
- Recruiters become wildly productive.
- Talent marketers engage with extreme efficiency.
- Talent leaders optimise hiring processes.
- Managers build stronger-performing teams.
- HR aligns employee development with company goals.
- HRIT easily integrates existing HR tech to create a holistic infrastructure.
See why Phenom continues to be recognised as industry leading, book a demo.
Click here for a personalised demo of Phenom’s Workforce Intelligence solution to learn more about how to set your employees up for career success.
About Phenom
Phenom has a purpose of helping a billion people find the right work. Through AI-powered talent experiences, employers use Phenom to hire and onboard employees faster, develop them to their full potential, and retain them longer. The Phenom Intelligent Talent Experience platform seamlessly connects candidates, employees, recruiters, talent marketers, talent leaders, hiring managers, HR and HRIT — empowering diverse and global enterprises with innovative products including Phenom X+ Generative AI, Career Site, Chatbot, CMS, Talent CRM, X+ Screening, Automated Interview Scheduling, Interview Intelligence, Talent Experience Engine, Campaigns, University Recruiting, Contingent Talent Hiring, Onboarding, Talent Marketplace, Workforce Intelligence, Career Pathing, Gigs, Mentoring, and Referrals.
Phenom has earned accolades including: Inc. 5000’s fastest-growing companies (5 consecutive years), Deloitte Technology's Fast 500 (4 consecutive years), five Brandon Hall ‘Excellence in Technology’ awards including Gold for ‘Best Advance in AI for Business Impact,’ Business Intelligence Group's Artificial Intelligence Excellence Awards (3 consecutive years), and a regional Timmy Award for launching and optimising HelpOneBillion.com (2020).
Headquartered in Greater Philadelphia, Phenom also has offices in India, Israel, the Netherlands, Germany and the United Kingdom.
For more information, please visit www.phenom.com. Connect with Phenom on LinkedIn, X, Facebook, YouTube and Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241010930504/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IEO and Laife Reply Join Forces to Digitalise the Biobank Through Artificial Intelligence10.2.2026 10:00:00 CET | Press release
The two partners launch “Bianca”, the first large-scale digitalisation initiative in Italy focused on histopathological samples, aimed at training AI algorithms to support pathologists’ diagnostic activities. The Pathology Division of the European Institute of Oncology (IEO) and Laife Reply, the Reply Group company specialised in AI and Big Data solutions for the healthcare sector, have entered into a collaboration to develop Bianca, the first project in Italy aimed at creating an AI-based digital biobank designed as an integral part of clinical diagnostic practice. The initiative is part of a broader technological innovation journey that structurally integrates research and development into routine diagnostic processes in pathology, transforming the traditional histopathological sample workflow into an end-to-end digital ecosystem. The complete digitalisation of histopathological and molecular diagnostic workflows aims to make analysis more efficient, scalable and reproducible, laying
OPEX® Corporation Introduces the Velo™ Series of Premium Desktop and High Production Document Scanners10.2.2026 10:00:00 CET | Press release
OPEX® Corporation, a global leader in Next Generation Automation providing innovative solutions for warehouse, document and mail automation, has announced the launch of its Velo™ Series powered by InoTec, a new class of premium desktop and free standing high production scanners. The OPEX Velo scanners are engineered to deliver exceptional performance, reliability and image quality and offer industry-standard TWAIN/ISIS connectivity to help simplify deployment into existing capture environments. These state-of-the-art scanners are ideal for service bureaus, government agencies, healthcare providers and enterprise capture operations. “The Velo Series powered by InoTec introduces an entirely new class of scanners to the OPEX portfolio, expanding the options available to both our current customers and organizations considering OPEX for the first time,” said Dann Worrell, President, Document and Mail Automation, OPEX. “By broadening our offerings, we can better align the right solution with
New ZOLL Zenix Monitor/Defibrillator Receives MDR Approval10.2.2026 10:00:00 CET | Press release
ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that Zenix®, the company’s most clinically advanced and easy-to-use professional monitor/defibrillator, is approved under the European Union (EU) Medical Device Regulation 2017/745, commonly referred to as EU MDR. The Zenix monitor/defibrillator is a groundbreaking device that redefines efficiency, clarity, and intelligence in both EMS and hospital settings. Built from years of feedback from customers, Zenix combines intuitive design with powerful functionality to enhance patient care and automate workflows for ease-of-use. Featuring a large, durable touchscreen, Zenix provides critical information when it’s needed. With on-the-fly customization, healthcare professionals can make real-time adjustments, helping them stay in control during high-pressure situations. Equipped with ZOLL’s innovative Real BVM Help® and exclusive Real CPR Help® technology, Zenix gives healthcare pro
Expereo Elevates expereoOne with New Digital Case Management Capabilities, Delivering Faster, Clearer and More Predictable Service Resolution10.2.2026 10:00:00 CET | Press release
Expereo is redefining what’s possible for global enterprises at CiscoLive Amsterdam with the launch of its enhanced Digital Case Management (DCM) capability in expereoOne. As the world-leading managed Network as a Service (NaaS) provider, Expereo is putting customers firmly in control - slashing resolution times, cutting through operational noise and ensuring everyone is aligned every step of the way. With DCM, service issues are no longer bottlenecks: instead, enterprises experience swift, transparent outcomes, with every stakeholder empowered through a single, real-time view of progress. DCM is designed around a simple objective: enable enterprises to resolve issues faster, with greater clarity and full control, through a fully digital, software-first workflow inside expereoOne. Customers can create, manage and track cases end-to-end within a single platform, ensuring predictable, consistent and aligned service experiences across their global network footprint. Unified, digital-first
U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 110.2.2026 09:15:00 CET | Press release
This FDA Acceptance is a Milestone for People Living with Narcolepsy Type 1 Who Need New and Different Treatment OptionsOveporexton is an Orexin Agonist Designed to Restore Orexin Signaling and Address the Underlying Orexin Deficiency that Causes Narcolepsy Type 1The Prescription Drug User Fee Act (PDUFA) Target Action Date is the Third Quarter of this Calendar Year Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted Priority Review for oveporexton (TAK-861) for the treatment of narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of this calendar year. Takeda remains on track to potentially bring the first approved orexin agonist treatment to people living
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom